Vanda Pharmaceuticals Inc (NASDAQ:VNDA) 2017 Q4 Sentiment Report

April 17, 2018 - By Vivian Currie

Sentiment for Vanda Pharmaceuticals Inc (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc (NASDAQ:VNDA) institutional sentiment decreased to 1.17 in Q4 2017. Its down -0.26, from 1.43 in 2017Q3. The ratio has dropped, as 62 investment managers increased and opened new equity positions, while 53 sold and decreased their positions in Vanda Pharmaceuticals Inc. The investment managers in our partner’s database now possess: 39.77 million shares, up from 38.89 million shares in 2017Q3. Also, the number of investment managers holding Vanda Pharmaceuticals Inc in their top 10 equity positions decreased from 2 to 1 for a decrease of 1. Sold All: 19 Reduced: 34 Increased: 46 New Position: 16.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $776.80 million. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

The stock increased 1.33% or $0.2 during the last trading session, reaching $15.25. About 335,126 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 15.63% since April 17, 2017 and is uptrending. It has outperformed by 4.08% the S&P500.

Analysts await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings on May, 1. They expect $-0.09 earnings per share, up 47.06 % or $0.08 from last year’s $-0.17 per share. After $-0.04 actual earnings per share reported by Vanda Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 125.00 % negative EPS growth.

Armistice Capital Llc holds 4.06% of its portfolio in Vanda Pharmaceuticals Inc. for 2.68 million shares. Palo Alto Investors Llc owns 4.16 million shares or 2.72% of their US portfolio. Moreover, Great Point Partners Llc has 2.07% invested in the company for 797,531 shares. The California-based Venbio Select Advisor Llc has invested 1.39% in the stock. Birchview Capital Lp, a Vermont-based fund reported 88,000 shares.#img1#

Since January 1, 0001, it had 0 insider purchases, and 8 sales for $4.89 million activity.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Ratings analysis reveals 100% of Vanda’s analysts are positive. Out of 4 Wall Street analysts rating Vanda, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $20.0 while the high is $27.0. The stock’s average target of $23.50 is 54.10% above today’s ($15.25) share price. VNDA was included in 8 notes of analysts from October 19, 2017. On Monday, January 8 the stock rating was maintained by Oppenheimer with “Buy”. Oppenheimer maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rating on Monday, March 5. Oppenheimer has “Buy” rating and $27.0 target. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Buy” rating by Seaport Global on Wednesday, February 28. As per Sunday, November 12, the company rating was maintained by Oppenheimer. Oppenheimer maintained it with “Outperform” rating and $26 target in Monday, October 30 report. The firm has “Buy” rating by Jefferies given on Tuesday, February 13. The stock has “Buy” rating by Piper Jaffray on Thursday, October 19.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.